0001104659-24-069821.txt : 20240607 0001104659-24-069821.hdr.sgml : 20240607 20240607215653 ACCESSION NUMBER: 0001104659-24-069821 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240606 FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McKelligon Brian CENTRAL INDEX KEY: 0001857447 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40344 FILM NUMBER: 241031369 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE STREET 2: 6TH FLOOR CITY: MARLBOROUGH STATE: MA ZIP: 01752 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akoya Biosciences, Inc. CENTRAL INDEX KEY: 0001711933 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 475586242 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE STREET 2: 6TH FLOOR CITY: MARLBOROUGH STATE: MA ZIP: 01762 BUSINESS PHONE: 855.896.8401 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE STREET 2: 6TH FLOOR CITY: MARLBOROUGH STATE: MA ZIP: 01762 4 1 tm2416807-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-06-06 0 0001711933 Akoya Biosciences, Inc. AKYA 0001857447 McKelligon Brian 100 CAMPUS DRIVE, 6TH FLOOR MARLBOROUGH MA 01752 1 1 0 0 President and CEO 1 Common Stock 2024-06-06 4 M 0 7500 0.303 A 232233 D Common Stock 2024-06-06 4 S 0 7500 2.0085 D 224733 D Employee Stock Option (Right to Buy) 0.303 2024-06-06 4 M 0 7500 0.00 D 2027-11-09 Common Stock 7500 283129 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brian M. McKelligon dated August 16, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.03, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. The option, representing a right to purchase a total of 353,129 shares, became exercisable as follows: one-fourth of the shares vested on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on August 14, 2018, subject to reporting person's continuous employment. /s/ Brian McKelligon 2024-06-07